Risk of progression to symptomatic VL in individuals who seroconverted compared to individuals who did not seroconvert, calculated by groups with low, moderate or high rK39 titers at the time of seroconversion.
收藏NIAID Data Ecosystem2026-03-08 收录
下载链接：
https://figshare.com/articles/dataset/_Risk_of_progression_to_symptomatic_VL_in_individuals_who_seroconverted_compared_to_individuals_who_did_not_seroconvert_calculated_by_groups_with_low_moderate_or_high_rK39_titers_at_the_time_of_seroconversion_/910968
下载链接
链接失效反馈官方服务：
资源简介：
Please note: Individuals in the KALANET study (cohorts 1 and 2) are not included in this analysis of seroconversion because their serologic status was measured only once.
创建时间：
2014-01-23
